Paragon 28, Inc (FNA) Q3 2024 Earnings Call Transcript Summary
Paragon 28, Inc (FNA) Q3 2024 Earnings Call Transcript Summary
Adjusted EBITDA for Q3 2024 was a profit of $432,000, showing substantial improvement.The following is a summary of the Paragon 28, Inc (FNA) Q3 2024 Earnings Call Transcript:
以下是 Paragon 28, Inc（FNA）2024年第三季度業績會交易會議錄音摘要:
Financial Performance:
財務表現：
Paragon 28 reported Q3 2024 global revenue of $62.3 million, an 18.1% reported growth and 17.6% constant currency growth.
U.S. business revenue was $51.2 million, representing 14.8% reported growth.
Adjusted EBITDA for Q3 2024 was a profit of $432,000, showing substantial improvement.
Gross margin for the quarter was 74.1%, reflecting a slight sequential decrease.
Total operating expense was $54.6 million, showing a sequential improvement in cost management.
Free cash flow saw a significant improvement, marking a 69.5% better performance compared to the same quarter last year.
Paragon 28報告2024年第三季度全球營業收入爲6230萬美元，按報告計算增長了18.1%，按不變貨幣計算增長了17.6%。
美國業務營收爲5120萬美元，報告增長了14.8%。
2024年第三季度調整後的EBITDA爲43.2萬美元，顯示了顯著改善。
該季度的毛利率爲74.1%，反映了輕微的順序下降。
總營業費用爲5460萬美元，顯示了成本管理方面的連續改善。
自由現金流得到了顯著改善，較去年同季度表現提升了69.5%。
Business Progress:
業務進展:
Paragon 28 launched 13 new products in 2024, including highly strategic end markets and the first SMART 28 module.
The company expanded its U.S. sales rep team by 10.5% and saw a productivity increase of 4% across its rep base.
Paragon 28在2024年推出了13種新產品，包括高度戰略的終端市場和首個SMARt 28模塊。
公司將美國銷售代表團隊擴大了10.5%，在代表基礎上實現了4%的生產率增長。
Opportunities:
機會：
Continued focus on innovation will drive future growth, with 13 new products launched in critical areas like ankle fractures and ankle replacement.
The expansion into international core markets and the increase in active surgeon customers by 9% present significant growth opportunities.
繼續專注創新將推動未來增長，在關鍵領域如踝關節骨折和踝關節置換推出了13種新產品。
進軍國際核心市場並將活躍外科醫生客戶增加9%爲未來增長提供重要機會。
Risks:
風險：
Volatility in sales trends as previously experienced choppiness in market conditions could impact future performance.
Ongoing restructuring and cost optimization efforts entail execution risks which could affect operational stability.
銷售趨勢的波動會對未來業績造成影響，之前市場條件的波動可能會影響未來表現。
持續進行的重組和成本優化工作涉及執行風險，可能影響運營穩定性。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
